{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T16:09:42Z","timestamp":1787069382220,"version":"build-2736575974"},"reference-count":175,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100002803","name":"Fondazione Cariplo","doi-asserted-by":"publisher","award":["2015-0552"],"award-info":[{"award-number":["2015-0552"]}],"id":[{"id":"10.13039\/501100002803","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["atherosclerosis-journal.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1016\/j.atherosclerosis.2018.09.035","type":"journal-article","created":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T17:48:29Z","timestamp":1538416109000},"page":"286-298","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"special_numbering":"C","title":["Cholesteryl ester transfer protein: An enigmatic pharmacology \u2013 Antagonists and agonists"],"prefix":"10.1016","volume":"278","author":[{"given":"Shizuya","family":"Yamashita","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0195-7061","authenticated-orcid":false,"given":"Massimiliano","family":"Ruscica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Macchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Corsini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Matsuzawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cesare R.","family":"Sirtori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.atherosclerosis.2018.09.035_bib1","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMoa1107579","article-title":"Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy","volume":"365","author":"Investigators","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2018.09.035_bib2","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa1300955","article-title":"Effects of extended-release niacin with laropiprant in high-risk patients","volume":"371","author":"Group","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2018.09.035_bib3","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(05)67667-2","article-title":"Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial","volume":"366","author":"Keech","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2018.09.035_bib4","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1056\/NEJMoa1001282","article-title":"Effects of combination lipid therapy in type 2 diabetes mellitus","volume":"362","author":"Group","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2018.09.035_bib5","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1080\/13543784.2017.1312339","article-title":"PPAR-alpha agonists are still on the rise: an update on clinical and experimental findings","volume":"26","author":"Ferri","year":"2017","journal-title":"Expet Opin. Invest. Drugs"},{"key":"10.1016\/j.atherosclerosis.2018.09.035_bib6","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1194\/jlr.R082735","article-title":"Cholesteryl ester transfer protein and its inhibitors","volume":"59","author":"Shrestha","year":"2018","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.atherosclerosis.2018.09.035_bib7","first-page":"299","article-title":"Cholesteryl ester transfer protein inhibitors as agents to reduce coronary heart disease risk","volume":"36","author":"Barter","year":"2018","journal-title":"Cardiol. Clin."},{"key":"10.1016\/j.atherosclerosis.2018.09.035_bib8","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.phrs.2017.12.028","article-title":"Present therapeutic role of cholesteryl ester transfer protein inhibitors","volume":"128","author":"Ferri","year":"2018","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.atherosclerosis.2018.09.035_bib9","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/0026-0495(93)90041-L","article-title":"Mechanisms of high-density lipoprotein reduction after probucol treatment: changes in plasma cholesterol esterification\/transfer and lipase activities","volume":"42","author":"Chiesa","year":"1993","journal-title":"Metabolism"},{"key":"10.1016\/j.atherosclerosis.2018.09.035_bib10","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.atherosclerosis.2009.04.002","article-title":"Where are we with probucol: a new life for an old drug?","volume":"207","author":"Yamashita","year":"2009","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2018.09.035_bib11","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1093\/eurheartj\/ehw272","article-title":"2016 ESC\/EAS guidelines for the management of dyslipidaemias","volume":"37","author":"Catapano","year":"2016","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2018.09.035_bib12","doi-asserted-by":"crossref","first-page":"11067","DOI":"10.1021\/bi901564g","article-title":"Small discoidal pre-beta1 HDL particles are efficient acceptors of cell cholesterol via ABCA1 and ABCG1","volume":"48","author":"Favari","year":"2009","journal-title":"Biochemistry"},{"key":"10.1016\/j.atherosclerosis.2018.09.035_bib13","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.atherosclerosis.2011.11.034","article-title":"Genetic lecithin:cholesterol acyltransferase deficiency and cardiovascular disease","volume":"222","author":"Calabresi","year":"2012","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2018.09.035_bib14","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0305-0491(98)10038-X","article-title":"Phospholipid and cholesteryl ester transfer activities in plasma from 14 vertebrate species. Relation to atherogenesis susceptibility","volume":"120","author":"Guyard-Dangremont","year":"1998","journal-title":"Comp. Biochem. Physiol. B Biochem. Mol. Biol."},{"key":"10.1016\/j.atherosclerosis.2018.09.035_bib15","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/S0022-2275(20)36957-1","article-title":"Plasma cholesteryl ester transfer protein","volume":"34","author":"Tall","year":"1993","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.atherosclerosis.2018.09.035_bib16","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1007\/s11886-017-0940-0","article-title":"HDL cholesterol metabolism and the risk of CHD: new insights from human genetics","volume":"19","author":"Vitali","year":"2017","journal-title":"Curr. Cardiol. Rep."},{"key":"10.1016\/j.atherosclerosis.2018.09.035_bib17","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1046\/j.1365-2796.1997.00197.x","article-title":"The emergence of mouse models of atherosclerosis and their relevance to clinical research","volume":"242","author":"Smith","year":"1997","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.atherosclerosis.2018.09.035_bib18","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1161\/01.ATV.0000094961.74697.54","article-title":"Endothelial protection by high-density lipoproteins: from bench to bedside","volume":"23","author":"Calabresi","year":"2003","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.atherosclerosis.2018.09.035_bib19","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1111\/j.1365-2362.1991.tb01385.x","article-title":"Probucol increases cholesteryl ester transfer protein activity in hypercholesterolaemic patients","volume":"21","author":"Franceschini","year":"1991","journal-title":"Eur. J. Clin. Invest."},{"key":"10.1016\/j.atherosclerosis.2018.09.035_bib20","doi-asserted-by":"crossref","first-page":"7725","DOI":"10.1073\/pnas.84.21.7725","volume":"84","author":"Carew","year":"1987","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.atherosclerosis.2018.09.035_bib21","doi-asserted-by":"crossref","first-page":"29H","DOI":"10.1016\/0002-9149(86)90434-0","article-title":"Effects of probucol on xanthomata regression in familial hypercholesterolemia","volume":"57","author":"Yamamoto","year":"1986","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2018.09.035_bib22","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1148\/radiol.2017161435","article-title":"Achilles tendon xanthomas: fat-water separation at baseline and after treatment","volume":"285","author":"Griffith","year":"2017","journal-title":"Radiology"},{"key":"10.1016\/j.atherosclerosis.2018.09.035_bib23","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1016\/S0140-6736(82)92439-4","article-title":"Probucol and the QT interval","volume":"1","author":"Martz","year":"1982","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2018.09.035_bib24","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/0002-9149(94)90579-7","article-title":"The effect of probucol on femoral atherosclerosis: the Probucol Quantitative Regression Swedish Trial (PQRST)","volume":"74","author":"Walldius","year":"1994","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2018.09.035_bib25","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1172\/JCI112349","article-title":"Probucol inhibits oxidative modification of low density lipoprotein","volume":"77","author":"Parthasarathy","year":"1986","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.atherosclerosis.2018.09.035_bib26","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1172\/JCI117301","article-title":"Inhibition of hypercholesterolemia-induced atherosclerosis in the nonhuman primate by probucol. I. Is the extent of atherosclerosis related to resistance of LDL to oxidation?","volume":"94","author":"Sasahara","year":"1994","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.atherosclerosis.2018.09.035_bib27","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1161\/ATVBAHA.108.179226","article-title":"Dysfunctional HDL as a diagnostic and therapeutic target","volume":"30","author":"Smith","year":"2010","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.atherosclerosis.2018.09.035_bib28","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1093\/oxfordjournals.jbchem.a124516","article-title":"Large and cholesteryl ester-rich high-density lipoproteins in cholesteryl ester transfer protein (CETP) deficiency can not protect macrophages from cholesterol accumulation induced by acetylated low-density lipoproteins","volume":"116","author":"Ishigami","year":"1994","journal-title":"J. Biochem."},{"key":"10.1016\/j.atherosclerosis.2018.09.035_bib29","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1056\/NEJMoa1001689","article-title":"Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis","volume":"364","author":"Khera","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2018.09.035_bib30","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1056\/NEJMoa1409065","article-title":"HDL cholesterol efflux capacity and incident cardiovascular events","volume":"371","author":"Rohatgi","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2018.09.035_bib31","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.1194\/jlr.R035725","article-title":"Proteomic diversity of high density lipoproteins: our emerging understanding of its importance in lipid transport and beyond","volume":"54","author":"Shah","year":"2013","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.atherosclerosis.2018.09.035_bib32","doi-asserted-by":"crossref","first-page":"ra79","DOI":"10.1126\/scisignal.aaa2581","article-title":"HDL-bound sphingosine 1-phosphate acts as a biased agonist for the endothelial cell receptor S1P1 to limit vascular inflammation","volume":"8","author":"Galvani","year":"2015","journal-title":"Sci. Signal."},{"key":"10.1016\/j.atherosclerosis.2018.09.035_bib33","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1097\/MOL.0b013e32833bcdc1","article-title":"Antiatherogenic function of HDL particle subpopulations: focus on antioxidative activities","volume":"21","author":"Kontush","year":"2010","journal-title":"Curr. Opin. Lipidol."},{"key":"10.1016\/j.atherosclerosis.2018.09.035_bib34","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/S0022-2275(20)30466-1","article-title":"Characterization of the lipolytic activity of endothelial lipase","volume":"43","author":"McCoy","year":"2002","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.atherosclerosis.2018.09.035_bib35","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.atherosclerosis.2007.12.031","article-title":"Probucol markedly reduces HDL phospholipids and elevated prebeta1-HDL without delayed conversion into alpha-migrating HDL: putative role of angiopoietin-like protein 3 in probucol-induced HDL remodeling","volume":"200","author":"Miida","year":"2008","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2018.09.035_bib36","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1194\/jlr.M076927","article-title":"Small dense HDLs display potent vasorelaxing activity, reflecting their elevated content of sphingosine-1-phosphate","volume":"59","author":"Persegol","year":"2018","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.atherosclerosis.2018.09.035_bib37","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1159\/000362993","article-title":"HDL-bound sphingosine 1-phosphate (S1P) predicts the severity of coronary artery atherosclerosis","volume":"34","author":"Sattler","year":"2014","journal-title":"Cell. Physiol. Biochem."},{"key":"10.1016\/j.atherosclerosis.2018.09.035_bib38","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1097\/FJC.0b013e3182798abc","article-title":"Inhibition of suicidal erythrocyte death by probucol","volume":"61","author":"Shaik","year":"2013","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.atherosclerosis.2018.09.035_bib39","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1007\/s10495-015-1102-8","article-title":"Autophagic flux and autophagosome morphogenesis require the participation of sphingolipids","volume":"20","author":"Tommasino","year":"2015","journal-title":"Apoptosis"},{"key":"10.1016\/j.atherosclerosis.2018.09.035_bib40","first-page":"941","article-title":"Longevity syndromes: familial hypobeta and familial hyperalpha lipoproteinemia","volume":"88","author":"Glueck","year":"1976","journal-title":"J. Lab. Clin. Med."},{"key":"10.1016\/j.atherosclerosis.2018.09.035_bib41","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/0021-9150(84)90196-5","article-title":"Marked hyper-HDL2-cholesterolemia associated with premature corneal opacity. A case report","volume":"53","author":"Matsuzawa","year":"1984","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2018.09.035_bib42","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S1388-1981(00)00164-5","article-title":"Molecular biology and pathophysiological aspects of plasma cholesteryl ester transfer protein","volume":"1529","author":"Yamashita","year":"2000","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.atherosclerosis.2018.09.035_bib43","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0021-9150(00)00574-8","article-title":"Molecular mechanisms, lipoprotein abnormalities and atherogenicity of hyperalphalipoproteinemia","volume":"152","author":"Yamashita","year":"2000","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2018.09.035_bib44","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0021-9150(02)00327-1","article-title":"Prevalence and phenotypic spectrum of cholesteryl ester transfer protein gene mutations in Japanese hyperalphalipoproteinemia","volume":"166","author":"Maruyama","year":"2003","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2018.09.035_bib45","doi-asserted-by":"crossref","first-page":"110","DOI":"10.5551\/jat.11.110","article-title":"Molecular mechanisms of cholesteryl ester transfer protein deficiency in Japanese","volume":"11","author":"Nagano","year":"2004","journal-title":"J. Atherosclerosis Thromb."},{"key":"10.1016\/j.atherosclerosis.2018.09.035_bib46","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1172\/JCI114764","article-title":"Accumulation of apolipoprotein E-rich high density lipoproteins in hyperalphalipoproteinemic human subjects with plasma cholesteryl ester transfer protein deficiency","volume":"86","author":"Yamashita","year":"1990","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.atherosclerosis.2018.09.035_bib47","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1016\/0006-291X(90)90542-U","article-title":"Total deficiency of plasma cholesteryl ester transfer protein in subjects homozygous and heterozygous for the intron 14 splicing defect","volume":"170","author":"Yamashita","year":"1990","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.atherosclerosis.2018.09.035_bib48","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1016\/0026-0495(91)90097-G","article-title":"Characterization of plasma lipoproteins in patients heterozygous for human plasma cholesteryl ester transfer protein (CETP) deficiency: plasma CETP regulates high-density lipoprotein concentration and composition","volume":"40","author":"Yamashita","year":"1991","journal-title":"Metabolism"},{"key":"10.1016\/j.atherosclerosis.2018.09.035_bib49","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1172\/JCI116802","article-title":"A missense mutation in the cholesteryl ester transfer protein gene with possible dominant effects on plasma high density lipoproteins","volume":"92","author":"Takahashi","year":"1993","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.atherosclerosis.2018.09.035_bib50","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.atherosclerosis.2008.08.031","article-title":"Novel mutations of CETP gene in Italian subjects with hyperalphalipoproteinemia","volume":"204","author":"Cefalu","year":"2009","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2018.09.035_bib51","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1093\/abbs\/36.1.33","article-title":"A novel missense mutation (L296 Q) in cholesteryl ester transfer protein gene related to coronary heart disease","volume":"36","author":"Zheng","year":"2004","journal-title":"Acta Biochim. Biophys. Sin."},{"key":"10.1016\/j.atherosclerosis.2018.09.035_bib52","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.atherosclerosis.2009.01.006","article-title":"A novel homozygous mutation in CETP gene as a cause of CETP deficiency in a Caucasian kindred","volume":"205","author":"Calabresi","year":"2009","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2018.09.035_bib53","doi-asserted-by":"crossref","first-page":"3382","DOI":"10.1210\/jc.2005-2322","article-title":"An increased coronary risk is paradoxically associated with common cholesteryl ester transfer protein gene variations that relate to higher high-density lipoprotein cholesterol: a population-based study","volume":"91","author":"Borggreve","year":"2006","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.atherosclerosis.2018.09.035_bib54","doi-asserted-by":"crossref","first-page":"2777","DOI":"10.1001\/jama.299.23.2777","article-title":"Association of cholesteryl ester transfer protein genotypes with CETP mass and activity, lipid levels, and coronary risk","volume":"299","author":"Thompson","year":"2008","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.atherosclerosis.2018.09.035_bib55","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1038\/nature09270","article-title":"Biological, clinical and population relevance of 95 loci for blood lipids","volume":"466","author":"Teslovich","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.atherosclerosis.2018.09.035_bib56","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1161\/01.ATV.17.6.1053","article-title":"Genetic cholesteryl ester transfer protein deficiency is extremely frequent in the Omagari area of Japan. Marked hyperalphalipoproteinemia caused by CETP gene mutation is not associated with longevity","volume":"17","author":"Hirano","year":"1997","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.atherosclerosis.2018.09.035_bib57","doi-asserted-by":"crossref","first-page":"2917","DOI":"10.1172\/JCI118751","article-title":"Increased coronary heart disease in Japanese-American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL levels","volume":"97","author":"Zhong","year":"1996","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.atherosclerosis.2018.09.035_bib58","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1161\/01.CIR.101.16.1907","article-title":"Elevated HDL cholesterol is a risk factor for ischemic heart disease in white women when caused by a common mutation in the cholesteryl ester transfer protein gene","volume":"101","author":"Agerholm-Larsen","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2018.09.035_bib59","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1002\/ana.24780","article-title":"Genetic variants in CETP increase risk of intracerebral hemorrhage","volume":"80","author":"Anderson","year":"2016","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.atherosclerosis.2018.09.035_bib60","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1001\/jamacardio.2017.4177","article-title":"Association of CETP gene variants with risk for vascular and nonvascular diseases among Chinese adults","volume":"3","author":"Millwood","year":"2018","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.atherosclerosis.2018.09.035_bib61","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1161\/CIRCRESAHA.117.311145","article-title":"Protein-truncating variants at the cholesteryl ester transfer protein gene and risk for coronary heart disease","volume":"121","author":"Nomura","year":"2017","journal-title":"Circ. Res."},{"key":"10.1016\/j.atherosclerosis.2018.09.035_bib62","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1056\/NEJMoa0907687","article-title":"Genetic variant of the scavenger receptor BI in humans","volume":"364","author":"Vergeer","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2018.09.035_bib63","doi-asserted-by":"crossref","first-page":"e45660","DOI":"10.1371\/journal.pone.0045660","article-title":"Functional characterization of newly-discovered mutations in human SR-BI","volume":"7","author":"Chadwick","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.atherosclerosis.2018.09.035_bib64","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1126\/science.aad3517","article-title":"Rare variant in scavenger receptor BI raises HDL cholesterol and increases risk of coronary heart disease","volume":"351","author":"Zanoni","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.atherosclerosis.2018.09.035_bib65","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1093\/eurheartj\/ehy169","article-title":"Rare SCARB1 mutations associate with high-density lipoprotein cholesterol but not with coronary artery disease","volume":"39","author":"Helgadottir","year":"2018","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2018.09.035_bib66","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1161\/CIRCULATIONAHA.109.872705","article-title":"Association of circulating cholesteryl ester transfer protein activity with incidence of cardiovascular disease in the community","volume":"120","author":"Vasan","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2018.09.035_bib67","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1161\/CIRCULATIONAHA.109.875013","article-title":"Cholesteryl ester transfer protein and mortality in patients undergoing coronary angiography: the Ludwigshafen Risk and Cardiovascular Health study","volume":"121","author":"Ritsch","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2018.09.035_bib68","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1111\/eci.12248","article-title":"Decreased cholesterol efflux capacity in patients with low cholesteryl ester transfer protein plasma levels","volume":"44","author":"Scharnagl","year":"2014","journal-title":"Eur. J. Clin. Invest."},{"key":"10.1016\/j.atherosclerosis.2018.09.035_bib69","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1111\/j.1365-2362.2010.02313.x","article-title":"Cholesteryl ester transfer protein in patients with coronary heart disease","volume":"40","author":"Duwensee","year":"2010","journal-title":"Eur. J. Clin. Invest."},{"key":"10.1016\/j.atherosclerosis.2018.09.035_bib70","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1093\/eurheartj\/ehx163","article-title":"Extreme high high-density lipoprotein cholesterol is paradoxically associated with high mortality in men and women: two prospective cohort studies","volume":"38","author":"Madsen","year":"2017","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2018.09.035_bib71","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.113.000519","article-title":"Coronary heart disease risks associated with high levels of HDL cholesterol","volume":"3","author":"Wilkins","year":"2014","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.atherosclerosis.2018.09.035_bib72","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1016\/j.jacc.2016.08.038","article-title":"High-density lipoprotein cholesterol and cause-specific mortality in individuals without previous cardiovascular conditions: the CANHEART study","volume":"68","author":"Ko","year":"2016","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2018.09.035_bib73","doi-asserted-by":"crossref","first-page":"800","DOI":"10.5551\/jat.33449","article-title":"The relationship between very high levels of serum high-density lipoprotein cholesterol and cause-specific mortality in a 20-year follow-up study of Japanese general population","volume":"23","author":"Hirata","year":"2016","journal-title":"J. Atherosclerosis Thromb."},{"issue":"3","key":"10.1016\/j.atherosclerosis.2018.09.035_bib74","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.jacl.2018.01.014","article-title":"Association of extremely high levels of high-density lipoprotein cholesterol with cardiovascular mortality in a pooled analysis of 9 cohort studies including 43,407 individuals: the EPOCH-Japan study","volume":"12","author":"Hirata","year":"2018","journal-title":"J. Clin. Lipidol."},{"key":"10.1016\/j.atherosclerosis.2018.09.035_bib75","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1161\/01.ATV.11.1.71","article-title":"Detection of two species of low density lipoprotein particles in cholesteryl ester transfer protein deficiency","volume":"11","author":"Sakai","year":"1991","journal-title":"Arterioscler. Thromb."},{"key":"10.1016\/j.atherosclerosis.2018.09.035_bib76","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1111\/j.1365-2362.1995.tb01710.x","article-title":"Decreased affinity of low density lipoprotein (LDL) particles for LDL receptors in patients with cholesteryl ester transfer protein deficiency","volume":"25","author":"Sakai","year":"1995","journal-title":"Eur. J. Clin. Invest."},{"key":"10.1016\/j.atherosclerosis.2018.09.035_bib77","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1172\/JCI27602","article-title":"HDL from CETP-deficient subjects shows enhanced ability to promote cholesterol efflux from macrophages in an apoE- and ABCG1-dependent pathway","volume":"116","author":"Matsuura","year":"2006","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.atherosclerosis.2018.09.035_bib78","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0095925","article-title":"eNOS activation by HDL is impaired in genetic CETP deficiency","volume":"9","author":"Gomaraschi","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.atherosclerosis.2018.09.035_bib79","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1023\/A:1006887729274","article-title":"CETP and exchangeable apoproteins: common features in lipid binding activity","volume":"175","author":"Bolanos-Garcia","year":"1997","journal-title":"Mol. Cell. Biochem."},{"key":"10.1016\/j.atherosclerosis.2018.09.035_bib80","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1016\/j.bbalip.2017.09.004","article-title":"Assessing the mechanisms of cholesteryl ester transfer protein inhibitors","volume":"1862","author":"Zhang","year":"2017","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.atherosclerosis.2018.09.035_bib81","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1001\/jama.2011.1649","article-title":"Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial","volume":"306","author":"Nicholls","year":"2011","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.atherosclerosis.2018.09.035_bib82","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1056\/NEJMoa0706628","article-title":"Effects of torcetrapib in patients at high risk for coronary events","volume":"357","author":"Barter","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2018.09.035_bib83","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.atherosclerosis.2011.09.017","article-title":"Effect of dalcetrapib, a CETP modulator, on non-cholesterol sterol markers of cholesterol homeostasis in healthy subjects","volume":"219","author":"Niesor","year":"2011","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2018.09.035_bib84","doi-asserted-by":"crossref","first-page":"27406","DOI":"10.1016\/S0021-9258(19)74263-X","article-title":"Down-regulation of mRNA for the low density lipoprotein receptor in transgenic mice containing the gene for human cholesteryl ester transfer protein. Mechanism to explain accumulation of lipoprotein B particles","volume":"268","author":"Jiang","year":"1993","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.atherosclerosis.2018.09.035_bib85","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/S0140-6736(12)60312-2","article-title":"Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study","volume":"380","author":"Voight","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2018.09.035_bib86","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19041197","article-title":"PPAR agonists and metabolic syndrome: an established role?","volume":"19","author":"Botta","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.atherosclerosis.2018.09.035_bib87","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1161\/01.CIR.98.19.2088","article-title":"Mechanism of action of fibrates on lipid and lipoprotein metabolism","volume":"98","author":"Staels","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2018.09.035_bib88","doi-asserted-by":"crossref","first-page":"5336","DOI":"10.1002\/j.1460-2075.1996.tb00918.x","article-title":"PPARalpha and PPARgamma activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene","volume":"15","author":"Schoonjans","year":"1996","journal-title":"EMBO J."},{"key":"10.1016\/j.atherosclerosis.2018.09.035_bib89","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1172\/JCI115993","article-title":"Dietary cholesterol increases transcription of the human cholesteryl ester transfer protein gene in transgenic mice. Dependence on natural flanking sequences","volume":"90","author":"Jiang","year":"1992","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.atherosclerosis.2018.09.035_bib90","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1007\/s11745-008-3187-0","article-title":"Peroxisome proliferator-activated receptor alpha agonists regulate cholesterol ester transfer protein","volume":"43","author":"Beyer","year":"2008","journal-title":"Lipids"},{"key":"10.1016\/j.atherosclerosis.2018.09.035_bib91","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1194\/jlr.M700108-JLR200","article-title":"Fenofibrate increases HDL-cholesterol by reducing cholesteryl ester transfer protein expression","volume":"48","author":"van der Hoogt","year":"2007","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.atherosclerosis.2018.09.035_bib92","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.jnutbio.2014.02.008","article-title":"Fibrates and fish oil, but not corn oil, up-regulate the expression of the cholesteryl ester transfer protein (CETP) gene","volume":"25","author":"Raposo","year":"2014","journal-title":"J. Nutr. Biochem."},{"key":"10.1016\/j.atherosclerosis.2018.09.035_bib93","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/0021-9150(94)90124-4","article-title":"Effects of bezafibrate therapy on subfractions of plasma low-density lipoprotein and high-density lipoprotein, and on activities of lecithin:cholesterol acyltransferase and cholesteryl ester transfer protein in patients with hyperlipoproteinemia","volume":"106","author":"Homma","year":"1994","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2018.09.035_bib94","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.2337\/dc09-1935","article-title":"Pioglitazone decreases plasma cholesteryl ester transfer protein mass, associated with a decrease in hepatic triglyceride content, in patients with type 2 diabetes","volume":"33","author":"Jonker","year":"2010","journal-title":"Diabetes Care"},{"key":"10.1016\/j.atherosclerosis.2018.09.035_bib95","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1002\/dmrr.715","article-title":"Differential effect of pioglitazone (PGZ) and rosiglitazone (RGZ) on postprandial glucose and lipid metabolism in patients with type 2 diabetes mellitus: a prospective, randomized crossover study","volume":"23","author":"Chappuis","year":"2007","journal-title":"Diabetes Metab Res Rev"},{"key":"10.1016\/j.atherosclerosis.2018.09.035_bib96","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1111\/j.1755-5922.2010.00222.x","article-title":"PPAR-gamma agonism for cardiovascular and renal protection","volume":"29","author":"Sarafidis","year":"2011","journal-title":"Cardiovasc Ther"},{"key":"10.1016\/j.atherosclerosis.2018.09.035_bib97","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S0140-6736(14)61933-4","article-title":"Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial","volume":"385","author":"Neuschwander-Tetri","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2018.09.035_bib98","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.ejphar.2017.11.021","article-title":"Obeticholic acid raises LDL-cholesterol and reduces HDL-cholesterol in the Diet-Induced NASH (DIN) hamster model","volume":"818","author":"Briand","year":"2018","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.atherosclerosis.2018.09.035_bib99","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1194\/jlr.M038141","article-title":"Farnesoid X receptor activation increases cholesteryl ester transfer protein expression in humans and transgenic mice","volume":"54","author":"Gautier","year":"2013","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.atherosclerosis.2018.09.035_bib100","doi-asserted-by":"crossref","first-page":"5033","DOI":"10.1074\/jbc.273.9.5033","article-title":"Effect of antisense oligonucleotides against cholesteryl ester transfer protein on the development of atherosclerosis in cholesterol-fed rabbits","volume":"273","author":"Sugano","year":"1998","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.atherosclerosis.2018.09.035_bib101","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1172\/JCI114132","article-title":"Monoclonal antibody inhibition of cholesteryl ester transfer protein activity in the rabbit. Effects on lipoprotein composition and high density lipoprotein cholesteryl ester metabolism","volume":"84","author":"Whitlock","year":"1989","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.atherosclerosis.2018.09.035_bib102","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1161\/01.ATV.20.9.2106","article-title":"Vaccine-induced antibodies inhibit CETP activity in vivo and reduce aortic lesions in a rabbit model of atherosclerosis","volume":"20","author":"Rittershaus","year":"2000","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.atherosclerosis.2018.09.035_bib103","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1161\/CIRCRESAHA.117.311978","article-title":"Trials and tribulations of CETP inhibitors","volume":"122","author":"Tall","year":"2018","journal-title":"Circ. Res."},{"key":"10.1016\/j.atherosclerosis.2018.09.035_bib104","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S0021-9150(03)00137-0","article-title":"The safety and immunogenicity of a CETP vaccine in healthy adults","volume":"169","author":"Davidson","year":"2003","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2018.09.035_bib105","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1056\/NEJMoa1706444","article-title":"Effects of anacetrapib in patients with atherosclerotic vascular disease","volume":"377","author":"Group","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2018.09.035_bib106","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1002\/cpt.700","article-title":"Chronic administration of anacetrapib is associated with accumulation in adipose and slow elimination","volume":"102","author":"Krishna","year":"2017","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.atherosclerosis.2018.09.035_bib107","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/S0140-6736(15)60158-1","article-title":"Cholesterol ester transfer protein inhibition by TA-8995 in patients with mild dyslipidaemia (TULIP): a randomised, double-blind, placebo-controlled phase 2 trial","volume":"386","author":"Hovingh","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2018.09.035_bib108","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1161\/CIRCGENETICS.114.000663","article-title":"Pharmacogenomic determinants of the cardiovascular effects of dalcetrapib","volume":"8","author":"Tardif","year":"2015","journal-title":"Circ Cardiovasc Genet"},{"key":"10.1016\/j.atherosclerosis.2018.09.035_bib109","doi-asserted-by":"crossref","DOI":"10.1007\/s40262-018-0656-3","article-title":"Clinical pharmacokinetics and pharmacodynamics of dalcetrapib","author":"Black","year":"2018","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.atherosclerosis.2018.09.035_bib110","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1056\/NEJMoa1206797","article-title":"Effects of dalcetrapib in patients with a recent acute coronary syndrome","volume":"367","author":"Schwartz","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2018.09.035_bib111","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1124\/jpet.104.065748","article-title":"Novel regulatory properties of human type 9 adenylate cyclase","volume":"310","author":"Cumbay","year":"2004","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.atherosclerosis.2018.09.035_bib112","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCULATIONAHA.117.031134","article-title":"Adenylate cyclase type 9 (ADCY9) inactivation protects from atherosclerosis only in the absence of cholesteryl ester transfer protein (CETP)","author":"Rautureau","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2018.09.035_bib113","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1001\/jamacardio.2018.0569","article-title":"ADCY9 genetic variants and cardiovascular outcomes with evacetrapib in patients with high-risk vascular disease: a nested case-control study","volume":"3","author":"Nissen","year":"2018","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.atherosclerosis.2018.09.035_bib114","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1161\/ATVBAHA.116.307122","article-title":"CETP: pharmacogenomics-based response to the CETP inhibitor dalcetrapib","volume":"37","author":"Tardif","year":"2017","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.atherosclerosis.2018.09.035_bib115","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1001\/jama.2017.11467","article-title":"Association of genetic variants related to CETP inhibitors and statins with lipoprotein levels and cardiovascular risk","volume":"318","author":"Ference","year":"2017","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.atherosclerosis.2018.09.035_bib116","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1093\/ajcn\/23.9.1229","article-title":"Hypocholesterolemic effect of 4,4'-(isopropylidenedithio)-bis(2,6-di-t-butylphenol) (probucol)","volume":"23","author":"Barnhart","year":"1970","journal-title":"Am. J. Clin. Nutr."},{"key":"10.1016\/j.atherosclerosis.2018.09.035_bib117","doi-asserted-by":"crossref","first-page":"409","DOI":"10.2165\/00003495-197815060-00001","article-title":"Probucol: a review of its pharmacological properties and therapeutic use in patients with hypercholesterolaemia","volume":"15","author":"Heel","year":"1978","journal-title":"Drugs"},{"key":"10.1016\/j.atherosclerosis.2018.09.035_bib118","doi-asserted-by":"crossref","first-page":"688","DOI":"10.5414\/CP201525","article-title":"Pharmacokinetics and tolerability of probucol after multiple oral administrations in healthy volunteers","volume":"49","author":"Jeon","year":"2011","journal-title":"Int. J. Clin. Pharm. Ther."},{"key":"10.1016\/j.atherosclerosis.2018.09.035_bib119","doi-asserted-by":"crossref","first-page":"761","DOI":"10.2165\/00003495-198937060-00002","article-title":"Probucol. A reappraisal of its pharmacological properties and therapeutic use in hypercholesterolaemia","volume":"37","author":"Buckley","year":"1989","journal-title":"Drugs"},{"key":"10.1016\/j.atherosclerosis.2018.09.035_bib120","doi-asserted-by":"crossref","first-page":"5928","DOI":"10.1073\/pnas.84.16.5928","article-title":"Probucol prevents the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbit, an animal model for familial hypercholesterolemia","volume":"84","author":"Kita","year":"1987","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.atherosclerosis.2018.09.035_bib121","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/0021-9150(83)90102-8","article-title":"Effects of probucol on homozygous cases of familial hypercholesterolemia","volume":"48","author":"Yamamoto","year":"1983","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2018.09.035_bib122","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/0021-9150(93)90260-2","article-title":"Cholesterol-lowering drug therapy in a patient with receptor-negative homozygous familial hypercholesterolaemia","volume":"103","author":"Feher","year":"1993","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2018.09.035_bib123","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/0021-9150(92)90046-J","article-title":"Effect of low-dose probucol therapy on LDL oxidation and the plasma lipoprotein profile in male volunteers","volume":"97","author":"Cristol","year":"1992","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2018.09.035_bib124","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1007\/s10517-007-0399-x","article-title":"Relationship between free-radical lipid oxidation and efficiency of coronary angioplasty in coronary patients","volume":"144","author":"Kaminnyi","year":"2007","journal-title":"Bull. Exp. Biol. Med."},{"key":"10.1016\/j.atherosclerosis.2018.09.035_bib125","first-page":"37","article-title":"The role of oxidized lipoproteins in the pathogenesis of atherosclerosis","volume":"20","author":"Kita","year":"1992","journal-title":"Clin Exp Pharmacol Physiol Suppl"},{"key":"10.1016\/j.atherosclerosis.2018.09.035_bib126","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0021-9150(02)00023-0","article-title":"Comparison of the effects of alpha-tocopherol, ubiquinone-10 and probucol at therapeutic doses on atherosclerosis in WHHL rabbits","volume":"163","author":"Brasen","year":"2002","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2018.09.035_bib127","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1097\/01.fjc.0000194687.19335.59","article-title":"Probucol up-regulates paraoxonase 1 expression in hepatocytes of hypercholesterolemic rabbits","volume":"47","author":"Hong","year":"2006","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.atherosclerosis.2018.09.035_bib128","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1152\/physrev.00047.2003","article-title":"Role of oxidative modifications in atherosclerosis","volume":"84","author":"Stocker","year":"2004","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.atherosclerosis.2018.09.035_bib129","doi-asserted-by":"crossref","first-page":"2968","DOI":"10.1002\/jcp.25738","article-title":"Anti-atherosclerotic effects of vitamins D and E in suppression of atherogenesis","volume":"232","author":"Rashidi","year":"2017","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.atherosclerosis.2018.09.035_bib130","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1172\/JCI6391","article-title":"Dissociation of atherogenesis from aortic accumulation of lipid hydro(pero)xides in Watanabe heritable hyperlipidemic rabbits","volume":"104","author":"Witting","year":"1999","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.atherosclerosis.2018.09.035_bib131","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1161\/01.ATV.17.7.1289","article-title":"Effect of probucol treatment on gene expression of VCAM-1, MCP-1, and M-CSF in the aortic wall of LDL receptor-deficient rabbits during early atherogenesis","volume":"17","author":"Fruebis","year":"1997","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.atherosclerosis.2018.09.035_bib132","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/S0735-1097(01)01709-0","article-title":"Improved post-myocardial infarction survival with probucol in rats: effects on left ventricular function, morphology, cardiac oxidative stress and cytokine expression","volume":"39","author":"Sia","year":"2002","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2018.09.035_bib133","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1056\/NEJM198610233151702","article-title":"Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries","volume":"315","author":"Ludmer","year":"1986","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2018.09.035_bib134","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1161\/01.CIR.0000062682.40051.43","article-title":"Probucol promotes functional reendothelialization in balloon-injured rabbit aortas","volume":"107","author":"Lau","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2018.09.035_bib135","doi-asserted-by":"crossref","first-page":"15612","DOI":"10.1074\/jbc.M414256200","article-title":"Probucol protects against hypochlorite-induced endothelial dysfunction: identification of a novel pathway of probucol oxidation to a biologically active intermediate","volume":"280","author":"Witting","year":"2005","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.atherosclerosis.2018.09.035_bib136","doi-asserted-by":"crossref","first-page":"26071","DOI":"10.1074\/jbc.274.37.26071","article-title":"Nrf2, a Cap'n'Collar transcription factor, regulates induction of the heme oxygenase-1 gene","volume":"274","author":"Alam","year":"1999","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.atherosclerosis.2018.09.035_bib137","doi-asserted-by":"crossref","first-page":"7283","DOI":"10.1073\/pnas.1237725100","article-title":"Probucol prevents early coronary heart disease and death in the high-density lipoprotein receptor SR-BI\/apolipoprotein E double knockout mouse","volume":"100","author":"Braun","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.atherosclerosis.2018.09.035_bib138","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1124\/jpet.106.118612","article-title":"Probucol [4,4'-[(1-methylethylidene)bis(thio)]bis-[2,6-bis(1,1-dimethylethyl)phenol]] inhibits compensatory remodeling and promotes lumen loss associated with atherosclerosis in apolipoprotein E-deficient mice","volume":"321","author":"Wu","year":"2007","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.atherosclerosis.2018.09.035_bib139","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.ejphar.2007.05.050","article-title":"Probucol mediates vascular remodeling after percutaneous transluminal angioplasty via down-regulation of the ERK1\/2 signaling pathway","volume":"570","author":"Yang","year":"2007","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.atherosclerosis.2018.09.035_bib140","doi-asserted-by":"crossref","first-page":"66B","DOI":"10.1016\/S0002-9149(88)80055-9","article-title":"Selective reduction of cholesterol in HDL2 fraction by probucol in familial hypercholesterolemia and hyperHDL2 cholesterolemia with abnormal cholesteryl ester transfer","volume":"62","author":"Matsuzawa","year":"1988","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2018.09.035_bib141","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1161\/01.ATV.9.4.462","article-title":"Mechanisms of HDL reduction after probucol. Changes in HDL subfractions and increased reverse cholesteryl ester transfer","volume":"9","author":"Franceschini","year":"1989","journal-title":"Arteriosclerosis"},{"key":"10.1016\/j.atherosclerosis.2018.09.035_bib142","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1046\/j.1365-2362.1997.1040657.x","article-title":"High-density lipoproteins from probucol-treated patients have increased capacity to promote cholesterol efflux from mouse peritoneal macrophages loaded with acetylated low-density lipoproteins","volume":"27","author":"Ishigami","year":"1997","journal-title":"Eur. J. Clin. Invest."},{"key":"10.1016\/j.atherosclerosis.2018.09.035_bib143","doi-asserted-by":"crossref","first-page":"2422","DOI":"10.1161\/01.ATV.0000185834.98941.3d","article-title":"Probucol enhances the expression of human hepatic scavenger receptor class B type I, possibly through a species-specific mechanism","volume":"25","author":"Hirano","year":"2005","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.atherosclerosis.2018.09.035_bib144","doi-asserted-by":"crossref","first-page":"13011","DOI":"10.1021\/bi960734h","article-title":"Selective inhibition of free apolipoprotein-mediated cellular lipid efflux by probucol","volume":"35","author":"Tsujita","year":"1996","journal-title":"Biochemistry"},{"key":"10.1016\/j.atherosclerosis.2018.09.035_bib145","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S1388-1981(00)00061-5","article-title":"Apolipoprotein-mediated cellular cholesterol\/phospholipid efflux and plasma high density lipoprotein level in mice","volume":"1485","author":"Tsujita","year":"2000","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.atherosclerosis.2018.09.035_bib146","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1161\/01.ATV.0000148706.15947.8a","article-title":"Probucol inhibits ABCA1-mediated cellular lipid efflux","volume":"24","author":"Favari","year":"2004","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.atherosclerosis.2018.09.035_bib147","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/0891-5849(93)90510-2","article-title":"Probucol as an antioxidant and antiatherogenic drug","volume":"14","author":"Kuzuya","year":"1993","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.atherosclerosis.2018.09.035_bib148","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1161\/01.ATV.11.5.1266","article-title":"Attenuation of atherosclerosis in a modified strain of hypercholesterolemic Watanabe rabbits with use of a probucol analogue (MDL 29,311) that does not lower serum cholesterol","volume":"11","author":"Mao","year":"1991","journal-title":"Arterioscler. Thromb."},{"key":"10.1016\/j.atherosclerosis.2018.09.035_bib149","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1161\/ATVBAHA.115.306376","article-title":"Probucol-oxidized products, spiroquinone and diphenoquinone, promote reverse cholesterol transport in mice","volume":"36","author":"Yakushiji","year":"2016","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.atherosclerosis.2018.09.035_bib150","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1194\/jlr.M900122-JLR200","article-title":"Pharmacological inhibition of ABCA1 degradation increases HDL biogenesis and exhibits antiatherogenesis","volume":"50","author":"Arakawa","year":"2009","journal-title":"J. Lipid Res."},{"issue":"7","key":"10.1016\/j.atherosclerosis.2018.09.035_bib151","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1161\/ATVBAHA.118.311056","article-title":"Hepatic overexpression of endothelial lipase lowers HDL (High-Density lipoprotein) but maintains reverse cholesterol transport in mice: role of SR-BI (scavenger receptor class B type I)\/ABCA1 (ATP-Binding cassette transporter A1)-dependent pathways","volume":"38","author":"Takiguchi","year":"2018","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.atherosclerosis.2018.09.035_bib152","doi-asserted-by":"crossref","first-page":"643","DOI":"10.5551\/jat.12807","article-title":"Effect of probucol on antioxidant properties of HDL in patients with heterozygous familial hypercholesterolemia","volume":"19","author":"Inagaki","year":"2012","journal-title":"J. Atherosclerosis Thromb."},{"key":"10.1016\/j.atherosclerosis.2018.09.035_bib153","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/1476-511X-10-210","article-title":"Probucol alleviates atherosclerosis and improves high density lipoprotein function","volume":"10","author":"Zhong","year":"2011","journal-title":"Lipids Health Dis."},{"key":"10.1016\/j.atherosclerosis.2018.09.035_bib154","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1097\/MOL.0000000000000199","article-title":"Did we abandon probucol too soon?","volume":"26","author":"Yamashita","year":"2015","journal-title":"Curr. Opin. Lipidol."},{"issue":"Suppl","key":"10.1016\/j.atherosclerosis.2018.09.035_bib155","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1016\/S0021-9150(97)06117-0","article-title":"Mechanical determinants of plaque modeling, remodeling and disruption","volume":"131","author":"Glagov","year":"1997","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2018.09.035_bib156","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1056\/NEJM199708073370601","article-title":"Probucol and multivitamins in the prevention of restenosis after coronary angioplasty. Multivitamins and Probucol Study Group","volume":"337","author":"Tardif","year":"1997","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2018.09.035_bib157","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1161\/01.CIR.99.1.30","article-title":"Effects of probucol on vascular remodeling after coronary angioplasty. Multivitamins and Protocol Study Group","volume":"99","author":"Cote","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2018.09.035_bib158","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/S0735-1097(01)01783-1","article-title":"Effects of probucol and pravastatin on common carotid atherosclerosis in patients with asymptomatic hypercholesterolemia. Fukuoka Atherosclerosis Trial (FAST)","volume":"39","author":"Sawayama","year":"2002","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2018.09.035_bib159","doi-asserted-by":"crossref","first-page":"292","DOI":"10.5551\/jat.E610","article-title":"Long-term probucol treatment prevents secondary cardiovascular events: a cohort study of patients with heterozygous familial hypercholesterolemia in Japan","volume":"15","author":"Yamashita","year":"2008","journal-title":"J. Atherosclerosis Thromb."},{"key":"10.1016\/j.atherosclerosis.2018.09.035_bib160","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.atherosclerosis.2011.09.051","article-title":"Probucol therapy improves long-term (>10-year) survival after complete revascularization: a propensity analysis","volume":"220","author":"Kasai","year":"2012","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2018.09.035_bib161","doi-asserted-by":"crossref","first-page":"746","DOI":"10.5551\/jat.32813","article-title":"Rationale and design of the PROSPECTIVE trial: probucol trial for secondary prevention of atherosclerotic events in patients with prior coronary heart disease","volume":"23","author":"Yamashita","year":"2016","journal-title":"J. Atherosclerosis Thromb."},{"key":"10.1016\/j.atherosclerosis.2018.09.035_bib162","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/S1474-4422(18)30128-5","article-title":"Prevention of cardiovascular events in Asian patients with ischaemic stroke at high risk of cerebral haemorrhage (PICASSO): a multicentre, randomised controlled trial","volume":"17","author":"Kim","year":"2018","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.atherosclerosis.2018.09.035_bib163","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1097\/MOL.0b013e32832aee68","article-title":"Molecular mechanisms underlying the antiatherosclerotic and antidiabetic effects of probucol, succinobucol, and other probucol analogues","volume":"20","author":"Stocker","year":"2009","journal-title":"Curr. Opin. Lipidol."},{"key":"10.1016\/j.atherosclerosis.2018.09.035_bib164","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.atherosclerosis.2014.09.008","article-title":"Elsibucol inhibits atherosclerosis following arterial injury: multifunctional effects on cholesterol levels, oxidative stress and inflammation","volume":"237","author":"Dussault","year":"2014","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2018.09.035_bib165","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1517\/13543780902849244","article-title":"Succinobucol: review of the metabolic, antiplatelet and cardiovascular effects","volume":"18","author":"Muldrew","year":"2009","journal-title":"Expet Opin. Invest. Drugs"},{"key":"10.1016\/j.atherosclerosis.2018.09.035_bib166","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1016\/S0960-894X(02)00516-4","article-title":"Novel phenolic antioxidants as multifunctional inhibitors of inducible VCAM-1 expression for use in atherosclerosis","volume":"12","author":"Meng","year":"2002","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.atherosclerosis.2018.09.035_bib167","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1124\/jpet.103.059733","article-title":"Selective inhibition of endothelial and monocyte redox-sensitive genes by AGI-1067: a novel antioxidant and anti-inflammatory agent","volume":"308","author":"Kunsch","year":"2004","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.atherosclerosis.2018.09.035_bib168","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1124\/jpet.102.048132","article-title":"AGI-1067: a multifunctional phenolic antioxidant, lipid modulator, anti-inflammatory and antiatherosclerotic agent","volume":"305","author":"Sundell","year":"2003","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.atherosclerosis.2018.09.035_bib169","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1161\/01.CIR.0000047525.58618.3C","article-title":"Effects of AGI-1067 and probucol after percutaneous coronary interventions","volume":"107","author":"Tardif","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2018.09.035_bib170","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.atherosclerosis.2006.11.039","article-title":"Effects of the antioxidant succinobucol (AGI-1067) on human atherosclerosis in a randomized clinical trial","volume":"197","author":"Tardif","year":"2008","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2018.09.035_bib171","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1016\/S0140-6736(08)60763-1","article-title":"Effects of succinobucol (AGI-1067) after an acute coronary syndrome: a randomised, double-blind, placebo-controlled trial","volume":"371","author":"Tardif","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2018.09.035_bib172","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.atherosclerosis.2011.07.023","article-title":"Leoligin, the major lignan from Edelweiss, activates cholesteryl ester transfer protein","volume":"219","author":"Duwensee","year":"2011","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2018.09.035_bib173","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.yjmcc.2016.08.003","article-title":"Leoligin, the major lignan from Edelweiss, inhibits 3-hydroxy-3-methyl-glutaryl-CoA reductase and reduces cholesterol levels in ApoE-\/- mice","volume":"99","author":"Scharinger","year":"2016","journal-title":"J. Mol. Cell. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2018.09.035_bib174","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1161\/CIRCULATIONAHA.110.009704","article-title":"Pharmacologic suppression of hepatic ATP-binding cassette transporter 1 activity in mice reduces high-density lipoprotein cholesterol levels but promotes reverse cholesterol transport","volume":"124","author":"Yamamoto","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2018.09.035_bib175","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/j.bbrc.2017.05.017","article-title":"Reversal of adipose tissue loss by probucol in mice with deficiency of both scavenger receptor class B type 1 and LDL receptor on high fat diet","volume":"497","author":"Guo","year":"2018","journal-title":"Biochem. Biophys. Res. Commun."}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915018314084?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915018314084?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T16:23:57Z","timestamp":1762187037000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021915018314084"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":175,"alternative-id":["S0021915018314084"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2018.09.035","relation":{},"ISSN":["0021-9150"],"issn-type":[{"value":"0021-9150","type":"print"}],"subject":[],"published":{"date-parts":[[2018,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cholesteryl ester transfer protein: An enigmatic pharmacology \u2013 Antagonists and agonists","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2018.09.035","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}